ACH-SITAGLIPTIN: May exceed established acceptable intake limit for NTTP.

The affected lots may exceed the established acceptable intake limit for 7-nitroso-3-(trifluoromethyl)- 5,6,7,8-tetrahydro[1,2,4] triazolo-[4,3-a]pyrazine (NTTP).

Product safety

Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns. Contact the recalling firm if you have any questions about the recall. Report any health product related side effects to Health Canada. Report any other health product safety complaints to Health Canada.

ACH-SITAGLIPTIN

RA-75915